Sindrup 2001.

Methods	Double blind placebo controlled crossover design, five weeks. Two five week periods, at least one week washout, no carry over effect Inclusion criteria: age at least 20 years, duration of symptoms at least six months
Participants	Polyneuropathy (diabetic 18, non‐diabetic 29). 54 participants (47 final number) Mean age 58 years (range 30 to 82), 31 male and 16 female patients Pain score 14 (25 to 75 % CI: 9 to 19), mean consumption of paracetamol 500 mg six tablets / week (25 to 75 % CI: 0 to 22)
Interventions	St.John's wort (total hypericin) 2700 mcg daily orally, or placebo
Outcomes	Pain patients reported, 6‐item global improvement, sum pain score (0 to 40), paracetamol weekly consumption (number of 500 mg tablets), overall period reference On St.John's complete or good improvement 6/47, moderate 3/47, slight 4/47, no change 22/47, worse 12/47: on placebo complete or good improvement 0/47, moderate 2/47, slight 7/47, no change 25/47, worse 13/47 Pain on St.John's 14 (25 to 75 % CI: 7 to 21), on placebo 15 (9 to 19) Paracetamol consumption on St.John's 4 (25 to 75 % CI: 0 to 21), on placebo 5 (0 to18) Overall period preference 25 for St.John's, 16 for placebo, 6 no difference
Notes	Dropouts 7/54; on St John's 2 (1 SE and 1 lost to follow‐up), on placebo 4 (1 SE, 3 needed pain treatment), 1 inconsistent pain rating SE: 13/54 on St. Johns, 15/54 on placebo. Withdrawn due to SE 1/54 on St. johns, 1/54 on placebo QS = 5
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	A ‐ Adequate